Targeted therapy in the management of advanced gastric cancer: Are we making progress in the Era of personalized medicine?

Oncologist

Volumn 17, Issue 3, 2012, Pages 346-358

  Wong, Hilda ^a   Yau, Thomas ^a,b,c  

^a Division of Hematology and Medical Oncology   (Hong Kong)

^b QUEEN MARY HOSPITAL   (Hong Kong)

^c UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Advanced gastric cancer; Angiogenic pathway; Biomarker; Epidermal growth factor pathway; Targeted therapy

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CETUXIMAB; CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; EPIDERMAL GROWTH FACTOR RECEPTOR 4; EVEROLIMUS; FLUOROPYRIMIDINE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; LAPATINIB; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE; OXALIPLATIN; PACLITAXEL; PANITUMUMAB; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3, 4, 5 TRISPHOSPHATE 3 PHOSPHATASE; PLACEBO; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN KINASE B; RAF PROTEIN; RAS PROTEIN; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR;

ADVANCED CANCER; ANGIOGENESIS; ARTICLE; ASTHENIA; BLEEDING; CANCER CHEMOTHERAPY; CARDIOTOXICITY; CARDIOVASCULAR DISEASE; DIARRHEA; FATIGUE; FLUORESCENCE IN SITU HYBRIDIZATION; GASTROINTESTINAL HEMORRHAGE; HEART INFARCTION; HUMAN; HYPERTENSION; IMMUNOHISTOCHEMISTRY; INTESTINE PERFORATION; MOLECULARLY TARGETED THERAPY; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUTROPENIA; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RASH; SIGNAL TRANSDUCTION; STOMACH CANCER; THROMBOEMBOLISM; TREATMENT RESPONSE; VENOUS THROMBOEMBOLISM; VOMITING;

ANTIBODIES, MONOCLONAL, HUMANIZED; BIOMARKERS, PHARMACOLOGICAL; CLINICAL TRIALS, PHASE II AS TOPIC; DISEASE-FREE SURVIVAL; HUMANS; INDIVIDUALIZED MEDICINE; MOLECULAR TARGETED THERAPY; NEOPLASM STAGING; ONCOGENE PROTEIN V-AKT; PHOSPHATIDYLINOSITOL 3-KINASE; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; STOMACH NEOPLASMS; TOR SERINE-THREONINE KINASES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84859399146     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2011-0311     Document Type: Article

References (154)

1. Siegel R, Ward E, Jemal A. Cancer statistics, 2011. CA Cancer J Clin 2011;41:212-236.
2. Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: Defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 2006;24:2137-2150.
3. Paoletti X, Oba K, Burzykowski T et al. Benefit of adjuvant chemotherapy for resectable gastric cancer: A meta-analysis. JAMA 2010;303:1729-1737.
4. Macdonald JS, Smalley SR, Benedetti J et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001;345: 725-730.
5. Wagner AD, Grothe W, Behl S et al. Chemotherapy for advanced gastric cancer. Cochrane Database Syst Rev 2005;(2):CD004064.
6. Cunningham D, Starling N, Rao S et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 2008;358: 36-46.
7. Tanabe K, Suzuki T, Tokumoto N et al. Combination therapy with docetaxel and S-1 as a first-line treatment in patients with advanced or recurrent gastric cancer: A retrospective analysis. World J Surg Oncol 2010;8:40.
8. Van Cutsem E, Moiseyenko VM, Tjulandin S et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: A report of the V325 Study Group. J Clin Oncol 2006;24: 4991-4997.
9. Dank M, Zaluski J, Barone C et al. Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction. Ann Oncol 2008;19: 1450-1457.
10. Wu K, Nie Y, Guo C et al. Molecular basis of therapeutic approaches to gastric cancer. J Gastroenterol Hepatol 2009;24:37-41.
11. Yin M, Hu Z, Tan D et al. Molecular epidemiology of genetic susceptibility to gastric cancer: Focus on single nucleotide polymorphisms in gastric carcinogenesis. Am J Transl Res 2009;1:44-54.
12. Van Cutsem E, Kang Y, Chung H et al. Efficacy results from the ToGA trial: A phase III study of trastuzumab added to standard chemotherapy in first-line human epidermal growth factor receptor 2-positive advanced gastric cancer. J Clin Oncol 2009;27(15 suppl):LBA4509.
13. Bang YJ, Van Cutsem E, Feyereislova A et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2- positive advanced gastric or gastro-oesophageal junction cancer (ToGA): A phase 3, open-label, randomised controlled trial. Lancet 2010;376:687-697.
14. Dhanasekaran DN, Johnson GL. MAPKs: Function, regulation, role in cancer and therapeutic targeting. Oncogene 2007;26:3097-3099.
15. Schlessinger J. Common and distinct elements in cellular signaling via EGF and FGF receptors. Science 2004;306:1506-1507.
16. Yano T, Doi T, Ohtsu A et al. Comparison of HER2 gene amplification assessed by fluorescence in situ hybridization and HER2 protein expression assessed by immunohistochemistry in gastric cancer. Oncol Rep 2006;15:65-71.
17. Gravalos C, Màrquez A, García-Carbonero R et al. Correlation between Her2/neu overexpression/ amplification and clinicopathological parameters in advanced gastric cancer patients: A prospective study 2007 [abstract 189]. Presented at the 2007 American Society of Clinical Oncology Gastrointestinal Cancers Symposium, Orlando, FL, January 19-21, 2007.
18. Lordick F, Bang YJ, Kang YK et al. HER2- positive advanced gastric cancer: Similar HER2- positivity levels to breast cancer [abstract 3541]. Eur J Cancer 2007;5:271.
19. Koeppen HK, Wright BD, Burt AD et al. Overexpression of HER2/neu in solid tumours: An immunohistochemical survey. Histopathology 2001;38: 96-104.
20. Jaehne J, Urmacher C, Thaler HT et al. Expression of Her2/neu oncogene product p185 in correlation to clinicopathological and prognostic factors of gastric carcinoma. J Cancer Res Clin Oncol 1992; 118:474-479.
21. Im SA, Lee KE, Nam E et al. Potential prognostic significance of p185(HER2) overexpression with loss of PTEN expression in gastric carcinomas. Tumori 2005;91:513-521.
22. Uchino S, Tsuda H, Maruyama K et al. Overexpression of c-erbB-2 protein in gastric cancer. Its correlation with long-term survival of patients. Cancer 1993;72:3179-3184.
23. Nakajima M, Sawada H, Yamada Y et al. The prognostic significance of amplification and overexpression of c-met and c-erb B-2 in human gastric carcinomas. Cancer 1999;85:1894-1902.
24. Begnami MD, Fukuda E, Fregnani JH et al. Prognostic implications of altered human epidermal growth factor receptors (HERs) in gastric carcinomas: HER2 and HER3 are predictors of poor outcome. J Clin Oncol 2011;29:3030-3036.
25. Kim KC, Koh YW, Chang HM et al. Evaluation of HER2 protein expression in gastric carcinomas: Comparative analysis of 1,414 cases of whole-tissue sections and 595 cases of tissue microarrays. Ann Surg Oncol 2011;18:2833-2840.
26. Grabsch H, Sivakumar S, Gray S et al. HER2 expression in gastric cancer: Rare, heterogeneous and of no prognostic value- conclusions from 924 cases of two independent series. Cell Oncol 2010;32: 57-65.
27. Chua TC, Merrett ND. Clinicopathologic factors associated with HER2-positive gastric cancer and its impact on survival outcomes-a systematic review. Int J Cancer 2011 Jul 21 [Epub ahead of print]. doi: 10.1002/ijc.2692.
28. Moelans CB, van Diest PJ, Milne AN et al. Her- 2/neu testing and therapy in gastroesophageal adenocarcinoma. Patholog Res Int 2010;2011:674-182.
29. Cortés-Funes H, Rivera F, Alés I et al. Phase II of trastuzumab and cisplatin in patients with advanced gastric cancer with HER2/neu overexpression/amplification. J Clin Oncol 2007;15(18 suppl): 4613.
30. Nicholas G, Cripps C, Au HP et al. Early results of a trial of trastuzumab, cisplatin and docetaxel for the treatment of metastatic gastric cancer overexpressing HER-2 [abstract 1105]. ESMO 2006;17: 316.
31. U.S. Food and Drug Administration. Herceptin (trastuzumab) [prescribing information]. Available at http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/103792s5250lbl.pdf, accessed October 26, 2011.
32. European Medicines Agency. Herceptin [summary of product characteristics]. Available at http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000278/WC500074922.pdf, accessed October 26, 2011.
33. Rech J, Arnold D, Folprecht G et al. A pilot study of trastuzumab monotherapy in patients who progressed while on chemotherapy for metastatic or locally advanced HER-2 positive gastric cancer [abstract 1096]. ESMO 2006;17:314.
34. Kim MA, Lee HS, Lee HE et al. EGFR in gastric carcinomas: Prognostic significance of protein overexpression and high gene copy number. Histopathology 2008;52:738-746.
35. Lieto E, Ferraraccio F, Orditura M et al. Expression of vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR) is an independent prognostic indicator of worse outcome in gastric cancer patients. Ann Surg Oncol 2008;15:69-79.
36. Gamboa-Dominguez A, Dominguez-Fonseca C, Quintanilla-Martinez L et al. Epidermal growth factor receptor expression correlates with poor survival in gastric adenocarcinoma from Mexican patients: A multivariate analysis using a standardized immunohistochemical detection system. Mod Pathol 2004;17:579-587.
37. Matsubara J, Nishina T, Yamada Y et al. Impacts of excision repair cross-complementing gene 1 (ERCC1), dihydropyrimidine dehydrogenase, and epidermal growth factor receptor on the outcomes of patients with advanced gastric cancer. Br J Cancer 2008;98:832-839.
38. Pinto C, Fabio F, Siena S et al. Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study). Ann Oncol 2007;18:510-517.
39. Kanzler S, Trarbach T, Seufferlein T et al. German Arbeitsgemeinschaft Internistische O. Cetuximab with irinotecan/folinic acid/5-FU as first-line treatment in advanced gastric cancer: A nonrandomized multicenter AIO phase II study. J Clin Oncol 2009;27(15 suppl):4534.
40. Moehler M, Mueller A, Trarbach T et al. Cetuximab with irinotecan, folinic acid and 5-fluorouracil as first-line treatment in advanced gastroesophageal cancer: A prospective multicenter biomarker-oriented phase II study. Ann Oncol 2011;22:1358-1366.
41. Han SW, Oh DY, Im SA et al. Phase II study and biomarker analysis of cetuximab combined with modified FOLFOX6 in advanced gastric cancer. Br J Cancer 2009;100:298-304.
42. Lordick F, Luber B, Lorenzen S et al. Cetuximab plus oxaliplatin/leucovorin/5-fluorouracil in first-line metastatic gastric cancer: A phase II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). Br J Cancer 2010;102:500-505.
43. Kim C, Lee JL, Ryu MH et al. A prospective phase II study of cetuximab in combination with XELOX (capecitabine and oxaliplatin) in patients with metastatic and/or recurrent advanced gastric cancer. Invest New Drugs 2011;29:366-373.
44. Zhang X, Xu J, Shen L et al. A phase II study of cetuximab with cisplatin and capecitabine as firstline treatment in advanced gastric cancer [abstract LBA39]. Presented at the 2009 American Society of Clinical Oncology Gastrointestinal Cancers Symposium, San Francisco, CA, January 15-17, 2009.
45. Woell E, Greil R, Eisterer W et al. Oxaliplatin, irinotecan, and cetuximab in advanced gastric cancer. First efficacy results of a multicenter phase II trial (AGMT Gastric-2) [abstract 15587)]. Proc Am Soc Clin Oncol 2008;26:662s.
46. Pinto C, Fabio F, Barone C et al. Phase II study of cetuximab in combination with cisplatin and docetaxel in patients with untreated advanced gastric or gastro-oesophageal junction adenocarcinoma (DOCETUX study). Br J Cancer 2009;101:1261-1268.
47. Yeh K, Hsu C, Hsu C et al. Phase II study of cetuximab plus weekly cisplatin and 24-hour infusion of high-dose 5-fluorouracil and leucovorin for the first-line treatment of advanced gastric cancer. J Clin Oncol 2009;27(15 suppl):4567.
48. Enzinger PC, Burtness B, Hollis D et al. CALGB 80403/ECOG 1206: A randomized phase II study of three standard chemotherapy regimens (ECF, IC, FOLFOX) plus cetuximab in metastatic esophageal and GE junction cancer. J Clin Oncol 2010;28(15 suppl):4006.
49. Richards DA, Kocs DM, Spira AI et al. Results of docetaxel plus oxaliplatin (DOCOX) with or without cetuximab in patients with metastatic gastric and/or gastroesophageal junction adenocarcinoma: Results of a randomized phase II study. J Clin Oncol 2011;29(15 suppl):4015.
50. ClinicalTrials.gov. Erbitux in Combination With Xeloda and Cisplatin in Advanced Esophago-gastric Cancer (EXPAND). Available at http://www.clinicaltrials.gov/ct/show/NCT00678535, accessed January 21, 2012.
51. Tebbutt N, Sourjina T, Strickland AH et al. ATTAX2: Docetaxel plus cetuximab as second-line treatment for docetaxel refractory oesophago-gastric cancer-final results of a multicentre phase II trial by the AGITG [abstract 15554]. Proc Am Soc Clin Oncol 2008;26:659s.
52. Stein A, Al-Batran SE, Arnold D et al. Cetuximab with irinotecan as salvage therapy in heavily pretreated patients with metastatic gastric cancer. Presented at the 2007 American Society of Clinical Oncology Gastrointestinal Cancers Symposium, Orlando, FL, January 19-21, 2007.
53. Li J, Liu X, Wang BY et al. Phase II study of cetuximab in combination with modified FOLFIRI in patients with advanced gastric cancer who failed first-line chemotherapy (EFFI study). J Clin Oncol 2010;28(15 suppl):4107.
54. Van Cutsem E, Peeters M, Siena S et al. Openlabel phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 2007;25: 1658-1664.
55. ClinicalTrials.gov. REAL 3 Version 2.0: Trial of the Efficacy of Epirubicin, Oxaliplatin and Capecitabine (EOX) With or Without Panitumumab in Previously Untreated Advanced Oesophago-Gastric Cancer. Available at http://www.clinicaltrials.gov/ct/show/NCT00824785, accessed January 21, 2012.
56. Chau I, Okines AFC, Gonzalez de Castro D et al. REAL3: A multicenter randomized phase II/III trial of epirubicin, oxaliplatin, and capecitabine (EOC) versus modified (m) EOC plus panitumumab (P) in advanced oesophagogastric (OG) cancer- response rate (RR), toxicity, and molecular analysis from phase II. J Clin Oncol 2011;29(15 suppl):4131.
57. Rao S, Starling N, Cunningham D et al. Matuzumab plus epirubicin, cisplatin and capecitabine (ECX) compared with epirubicin, cisplatin and capecitabine alone as first-line treatment in patients with advanced oesophago-gastric cancer: A randomised, multicentre open-label phase II study. Ann Oncol 2010;21:2213-2219.
58. Kim YH, Sasaki Y, Lee KH et al. Randomized phase II study of nimotuzumab, an anti-EGFR antibody, plus irinotecan in patients with 5-fluorouracilbased regimen-refractory advanced or recurrent gastric cancer in Korea and Japan: Preliminary results. J Clin Oncol 2011;29(suppl 4):87.
59. Dragovich T, McCoy S, Fenoglio-Preiser CM et al. Phase II trial of erlotinib in gastroesophageal junction and gastric adenocarcinomas: SWOG 0127. J Clin Oncol 2006;24:4922-4927.
60. Rojo F, Tabernero J, Albanell J et al. Pharmacodynamic studies of gefitinib in tumor biopsy specimens from patients with advanced gastric carcinoma. J Clin Oncol 2006;24:4309-4316.
61. Doi T, Koizumi S, Siena S, al. e. Efficacy, tolerability and pharmacokinetics of gefitinib (ZD1839) in pretreated patients with metastatic gastric cancer. Proc Am Soc Clin Oncol 2003;22:1036.
62. Adelstein DJ, Rybicki L, Carrol MA et al. Phase II trial of gefitinib for recurrent or metastatic esophageal or gastroesophageal junction (GEJ) cancer. Proc Am Soc Clin Oncol 2005;23:A4054.
63. Wainberg ZA, Lin LS, DiCarlo B et al. Phase II trial of modified FOLFOX6 and erlotinib in patients with metastatic or advanced adenocarcinoma of the oesophagus and gastro-oesophageal junction. Br J Cancer 2011;105:760-765.
64. Iqbal S, Goldman H, Lenz HJ et al. S0413: A phase II SWOG study of GW572016 (lapatinib) as first line therapy in patients with advanced or metastatic gastric cancer. J Clin Oncol 2007;25:4621.
65. Hecht JR, Urba SG, Koehler M et al. Lapatinib monotherapy in recurrent upper gastrointestinal malignancy: Phase II efficacy and biomarker analyses [abstract 43]. Presented at the 2008 American Society of Clinical Oncology Gastrointestinal Cancers Symposium, Orlando, FL, January 25-27, 2008.
66. ClinicalTrials.gov. LOGiC - Lapatinib Optimization Study in ErbB2 (HER2) Positive Gastric Cancer: A Phase III Global, Blinded Study Designed to Evaluate Clinical Endpoints and Safety of Chemotherapy Plus Lapatinib. Available at http://www.clinicaltrials.gov/ct/show/NCT00680901, accessed January 21, 2012.
67. Satoh T, Bang Y, Wang J et al. Interim safety analysis from TYTAN: A phase III Asian study of lapatinib in combination with paclitaxel as secondline therapy in gastric cancer. J Clin Oncol 2010; 28(15 suppl):4057.
68. Shaw RJ, Cantley LC. Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature 2006; 441:424-430.
69. Murayama T, Inokuchi M, Takagi Y et al. Relation between outcomes and localisation of p-mTOR expression in gastric cancer. Br J Cancer 2009;100:782-788.
70. Bellacosa A, Kumar CC, Cristofano A et al. Activation of AKT kinases in cancer: Implications for therapeutic targeting. Adv Cancer Res 2005;94: 29-86.
71. Lang SA, Gaumann A, Koehl GE et al. Mammalian target of rapamycin is activated in human gastric cancer and serves as a target for therapy in an experimental model. Int J Cancer 2007;120:1803-1810.
72. Yu G, Wang J, Chen Y et al. Overexpression of phosphorylated mammalian target of rapamycin predicts lymph node metastasis and prognosis of Chinese patients with gastric cancer. Clin Cancer Res 2009;15:1821-1829.
73. Byun DS, Cho K, Ryu BK et al. Frequent monoallelic deletion of PTEN and its reciprocal association with PIK3CA amplification in gastric carcinoma. Int J Cancer 2003;104:318-327.
74. Li VS, Wong CW, Chan TL et al. Mutations of PIK3CA in gastric adenocarcinoma. BMC Cancer 2005;5:29.
75. Kang YH, Lee HS, Kim WH. Promoter methylation and silencing of PTEN in gastric carcinoma. Lab Invest 2002;82:285-291.
76. Linos K, Sheehan CE, Ross JS. Correlation of HER2 and PTEN status with clinical outcome in esophageal (E), gastric (G), and gastroesophageal junction (GEJ) adenocarcinomas (ACs). J Clin Oncol 2011;29(15 suppl):4066.
77. Doi T, Muro K, Boku N et al. Multicenter phase II study of everolimus in patients with previously treated metastatic gastric cancer. J Clin Oncol 2010; 28:1904-1910.
78. Jo JC, Lee JL, Ryu MH et al. Docetaxel monotherapy as a second-line treatment after failure of fluoropyrimidine and platinum in advanced gastric cancer: Experience of 154 patients with prognostic factor analysis. Jpn J Clin Oncol 2007;37:936-941.
79. Lee KW, Kim JH, Yun T et al. Phase II study of low-dose paclitaxel and cisplatin as a second-line therapy after 5-fluorouracil/platinum chemotherapy in gastric cancer. J Korean Med Sci 2007;22(suppl): S115-S121.
80. Park SH, Kim YS, Hong J et al. Mitomycin C plus S-1 as second-line therapy in patients with advanced gastric cancer: A noncomparative phase II study. Anticancer Drugs 2008;19:303-307.
81. Takiuchi H, Goto M, Imamura H et al. Multicenter phase II study for combination therapy with paclitaxel/doxifluridine to treat advanced/recurrent gastric cancer showing resistance to S-1 (OGSG 0302). Jpn J Clin Oncol 2008;38:176-181.
82. ClinicalTrials.gov. Safety and Efficacy of RAD001 (Everolimus) Monotherapy Plus Best Supportive Care in Patients With Advanced Gastric Cancer (AGC) (GRANITE-1). Available at http://www.clinicaltrials.gov/ct/show/NCT00879333, accessed January 21, 2012.
83. Normanno N, Tejpar S, Morgillo F et al. Implications for KRAS status and EGFR-targeted therapies in metastatic CRC. Nat Rev Clin Oncol 2009;6: 519-527.
84. Bardelli A, Siena S. Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer. J Clin Oncol 2010;28:1254-1261.
85. Lee SH, Lee JW, Soung YH et al. BRAF and KRAS mutations in stomach cancer. Oncogene 2003;22:6942-6945.
86. Hiyama T, Haruma K, Kitadai Y et al. K-ras mutation in Helicobacter pylori-associated chronic gastritis in patients with and without gastric cancer. Int J Cancer 2002;97:562-566.
87. Kim IJ, Park JH, Kang HC et al. Mutational analysis of BRAF and K-ras in gastric cancers: Absence of BRAF mutations in gastric cancers. Hum Genet 2003;114:118-120.
88. Lee KH, Lee JS, Suh C et al. Clinicopathologic significance of the K-ras gene codon 12 point mutation in stomach cancer. An analysis of 140 cases. Cancer 1995;75:2794-2801.
89. Nanus DM, Kelsen DP, Mentle IR et al. Infrequent point mutations of ras oncogenes in gastric cancers. Gastroenterology 1990;98:955-960.
90. Hongyo T, Buzard GS, Palli D et al. Mutations of the K-ras and p53 genes in gastric adenocarcinomas from a high-incidence region around Florence, Italy. Cancer Res 1995;55:2665-2672.
91. Park SR, Kook MC, Choi IJ et al. Predictive factors for the efficacy of cetuximab plus chemotherapy as salvage therapy in metastatic gastric cancer patients. Cancer Chemother Pharmacol 2010;65: 579-587.
92. Sun W, Powell M, O'Dwyer PJ et al. Phase II study of sorafenib in combination with docetaxel and cisplatin in the treatment of metastatic or advanced gastric and gastroesophageal junction adenocarcinoma: ECOG 5203. J Clin Oncol 2010;28:2947-2951.
93. Ilson D, Janjigian YY, Shah MA et al. Phase II trial of sorafenib in esophageal (E) and gastroesophageal junction (GEJ) cancer: Response and protracted stable disease observed in adenocarcinoma. J Clin Oncol 2011;29(15 suppl):4100.
94. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996;86:353-364.
95. Carmeliet P. Angiogenesis in health and disease. Nat Med 2003;9:653-660.
96. Maeda K, Chung YS, Ogawa Y et al. Prognostic value of vascular endothelial growth factor expression in gastric carcinoma. Cancer 1996;77:858-863.
97. Ni XF, Wu CP, Jiang JT. Serum VEGFR-3 and survival of advanced gastric cancer patients treated with FOLFOX. World J Gastroenterol 2010;16: 2163-2169.
98. Tanigawa N, Amaya H, Matsumura M et al. Extent of tumor vascularization correlates with prognosis and hematogenous metastasis in gastric carcinomas. Cancer Res 1996;56:2671-2676.
99. Guan X, Zhao H, Niu J et al. The VEGF -634G C promoter polymorphism is associated with risk of gastric cancer. BMC Gastroenterol 2009; 9:77.
100. Kim JG, Sohn SK, Chae YS et al. Vascular endothelial growth factor gene polymorphisms associated with prognosis for patients with gastric cancer. Ann Oncol 2007;18:1030-1036.
101. Schneider BP, Wang M, Radovich M et al. Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100. J Clin Oncol 2008;26:4672-4678.
102. Okines AF, Reynolds AR, Cunningham D. Targeting angiogenesis in esophagogastric adenocarcinoma. The Oncologist 2011;16:844-858.
103. Shah MA, Ramanathan RK, Ilson DH et al. Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma. J Clin Oncol 2006;24:5201-5206.
104. El-Rayes BF, Zalupski M, Bekai-Saab T et al. A phase II study of bevacizumab, oxaliplatin, and docetaxel in locally advanced and metastatic gastric and gastroesophageal junction cancers. Ann Oncol 2010;21:1999-2004.
105. Kelsen D, Jhawer M, Ilson D et al. Analysis of survival with modified docetaxel, cisplatin, fluorouracil, and bevacizumab in patients with metastatic gastroesophageal adenocarcinoma: Results of a phase II clinical trial. J Clin Oncol 2009;27:4512.
106. Cohenuram MK, Lacy J. FOLFOX6 and bevacizumab (FOLFOX6/B) for metastatic esophageal (E), gastroesophageal (GE), and gastric (G) adenocarcinoma: A single institution's initial clinical experience [abstract 74]. Presented at the 2008 American Society of Clinical Oncology Gastrointestinal Cancers Symposium, Orlando, FL, January 25-27, 2008.
107. Kang Y, Ohtsu A, Van Cutsem E et al. AVAGAST: A randomized, double-blind, placebocontrolled, phase III study of first-line capecitabine and cisplatin plus bevacizumab or placebo in patients with advanced gastric cancer (AGC). J Clin Oncol 2010; 28(18 suppl):LBA4007.
108. Ohtsu A, Shah MA, Van Cutsem E et al. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: A randomized, double-blind, placebo-controlled phase III study. J Clin Oncol 2011;29:3968-3976.
109. Bang YJ, Kang YK, Kang WK et al. Phase II study of sunitinib as second-line treatment for advanced gastric cancer. Invest New Drugs 2011;29: 1449-1458.
110. Moehler M, Hartmann JT, Lordick F et al. Sunitinib in patients with chemo-refractory metastatic gastric cancer: Preliminary results of an openlabel, prospective nonrandomized multicenter AIO phase II trial [abstract 61]. Presented at the 2009 American Society of Clinical Oncology Gastrointestinal Cancers Symposium, San Francisco, CA, January 15-17, 2009.
111. Alsina M, Ko AH, Garcia De Paredes M et al. Clinical and pharmacodynamic (PD) results of TEL0805 trial: A phase II study of telatinib (TEL) in combination with capecitabine (X) and cisplatin (P) as first-line treatment in patients (pts) with advanced gastric or gastroesophageal junction (GEJ) cancer. J Clin Oncol 2011;29(15 suppl):4122.
112. ClinicalTrials.gov. Study of Axitinib in Combination With Cisplatin and Capecitabine in Patients With Advanced Gastric Cancer. Available at http://clinicaltrials.gov/ct2/show/NCT00842244, accessed January 21, 2012.
113. Li J, Qin S, Xu J et al. A randomized, doubleblind, multicenter, phase II, three-arm, placebo-control study of apatinib as third-line treatment in patients with metastatic gastric carcinoma. J Clin Oncol 2011;29(15 suppl):4019.
114. Shah MA, Khanin R, Tang L et al. Molecular classification of gastric cancer: A new paradigm. Clin Cancer Res 2011;17:2693-2701.
115. Yamashita K, Sakuramoto S, Watanabe M. Genomic and epigenetic profiles of gastric cancer: Potential diagnostic and therapeutic applications. Surg Today 2011;41:24-38.
116. Sauter G, Lee J, Bartlett JM et al. Guidelines for human epidermal growth factor receptor 2 testing: Biologic and methodologic considerations. J Clin Oncol 2009;27:1323-1333.
117. Hofmann M, Stoss O, Shi D et al. HER2 status evaluation for gastric cancer: A consensus study [abstract 24]. Presented at the 2006 American Society of Clinical Oncology Gastrointestinal Cancers Symposium, San Francisco, Jauary, 26-28, 2006.
118. Nowell PC. The clonal evolution of tumor cell populations. Science 1976;194:23-28.
119. Richman SD, Chambers P, Seymour MT et al. Intra-tumoral heterogeneity of KRAS and BRAF mutation status in patients with advanced colorectal cancer (aCRC) and cost-effectiveness of multiple sample testing. Anal Cell Pathol (Amst) 2011;34: 61-66.
120. Choi YP, Shim HS, Gao MQ et al. Molecular portraits of intratumoral heterogeneity in human ovarian cancer. Cancer Lett 2011;307:62-71.
121. Nassar A, Radhakrishnan A, Cabrero IA et al. Intratumoral heterogeneity of immunohistochemical marker expression in breast carcinoma: A tissue microarray-based study. Appl Immunohistochem Mol Morphol 2010;18:433-441.
122. Guo Z, Wu F, Asplund A et al. Analysis of intratumoral heterogeneity of chromosome 3p deletions and genetic evidence of polyclonal origin of cervical squamous carcinoma. Mod Pathol 2001;14: 54-61.
123. Yoshimura A, Sugihara H, Ling ZQ et al. How wild-type TP53 is inactivated in undifferentiatedtype gastric carcinomas: Analyses of intratumoral heterogeneity in deletion and mutation of TP53. Pathobiology 2006;73:40-49.
124. Furuya T, Uchiyama T, Murakami T et al. Relationship between chromosomal instability and intratumoral regional DNA ploidy heterogeneity in primary gastric cancers. Clin Cancer Res 2000;6: 2815-2820.
125. Anzai H, Kitadai Y, Bucana CD et al. Intratumoral heterogeneity and inverse correlation between expression of E-cadherin and collagenase type IV in human gastric carcinomas. Differentiation 1996;60: 119-127.
126. Wainberg ZA, Anghel A, Desai AJ et al. Lapatinib, a dual EGFR and HER2 kinase inhibitor, selectively inhibits HER2-amplified human gastric cancer cells and is synergistic with trastuzumab in vitro and in vivo. Clin Cancer Res 2010;16:1509-1519.
127. Tanizaki J, Okamoto I, Takezawa K et al. Synergistic antitumor effect of S-1 and HER2-targeting agents in gastric cancer with HER2 amplification. Mol Cancer Ther 2010;9:1198-1207.
128. Burstein HJ, Sun Y, Dirix LY et al. Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer. J Clin Oncol 2010;28:1301-1307.
129. Vogel CL, Cobleigh MA, Tripathy D et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002;20:719-726.
130. Burstein HJ, Kuter I, Campos SM et al. Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer. J Clin Oncol 2001;19:2722-2730.
131. Bae SH, Ryoo HM, Kim MK et al. Effects of the proteasome inhibitor bortezomib alone and in combination with chemotherapeutic agents in gastric cancer cell lines. Oncol Rep 2008;19:1027-1032.
132. Ocean AJ, Schnoll-Sussman F, Keresztes R et al. Phase II study of PS-341 (bortezomib) with or without irinotecan in patients with advanced gastric adenocarcinomas. J Clin Oncol 2006;24(18 suppl): 4040.
133. Shah MA, Power DG, Kindler HL et al. A multicenter, phase II study of bortezomib (PS-341) in patients with unresectable or metastatic gastric and gastroesophageal junction adenocarcinoma. Invest New Drugs 2011;29:1475-1481.
134. Jatoi A, Dakhil SR, Foster NR et al. Bortezomib, paclitaxel, and carboplatin as a first-line regimen for patients with metastatic esophageal, gastric, and gastroesophageal cancer: Phase II results from the North Central Cancer Treatment Group (N044B). J Thorac Oncol 2008;3:516-520.
135. Migliore C, Giordano S. Molecular cancer therapy: Can our expectation be MET? Eur J Cancer 2008;44:641-651.
136. Ponzetto C, Giordano S, Peverali F et al. c-met is amplified but not mutated in a cell line with an activated met tyrosine kinase. Oncogene 1991;6:553-559.
137. Inoue T, Kataoka H, Goto K et al. Activation of c-Met (hepatocyte growth factor receptor) in human gastric cancer tissue. Cancer Sci 2004;95: 803-808.
138. Oliveira MJ, Costa AC, Costa AM et al. Helicobacter pylori induces gastric epithelial cell invasion in a c-Met and type IV secretion system-dependent manner. J Biol Chem 2006;281:34888-34896.
139. Smolen GA, Sordella R, Muir B et al. Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752. Proc Natl Acad Sci USA 2006;103:2316-2321.
140. Jhawer MP, Kindler HL, Wainberg ZA et al. Assessment of two dosing schedules of GSK1363089 (GSK089), a dual MET/VEGFR2 inhibitor, in metastatic gastric cancer (GC): Interim results of a multicenter phase II study. J Clin Oncol 2009;27(15 suppl):4502.
141. Lennerz JK, Kwak EL, Michael M et al. Identification of a small and lethal subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib by MET amplification. J Clin Oncol 2011;29(15 suppl):4130.
142. Watson GA, Zhang X, Stang MT et al. Inhibition of c-Met as a therapeutic strategy for esophageal adenocarcinoma. Neoplasia 2006;8:949-955.
143. Corso S, Ghiso E, Cepero V et al. Activation of HER family members in gastric carcinoma cells mediates resistance to MET inhibition. Mol Cancer 2010;9:121.
144. Bachleitner-Hofmann T, Sun MY, Chen CT et al. HER kinase activation confers resistance to MET tyrosine kinase inhibition in MET oncogene-addicted gastric cancer cells. Mol Cancer Ther 2008;7: 3499-3508.
145. Han ME, Lee YS, Baek SY et al. Hedgehog signaling regulates the survival of gastric cancer cells by regulating the expression of Bcl-2. Int J Mol Sci 2009;10:3033-3043.
146. ClinicalTrials.gov. Combination Chemotherapy With or Without GDC-0449 in Treating Patients With Advanced Stomach Cancer or Gastroesophageal Junction Cancer. Available at http://www.clinicaltrials.gov/ct/show/NCT00982592, accessed January 21, 2012.
147. Matsubara J, Yamada Y, Nakajima TE et al. Clinical significance of insulin-like growth factor type 1 receptor and epidermal growth factor receptor in patients with advanced gastric cancer. Oncology 2008;74:76-83.
148. Molife LR, Fong PC, Paccagnella L et al. The insulin-like growth factor-I receptor inhibitor figitumumab (CP-751,871) in combination with docetaxel in patients with advanced solid tumours: Results of a phase Ib dose-escalation, open-label study. Br J Cancer 2010;103:332-339.
149. Jang JH, Shin KH, Park JG. Mutations in fibroblast growth factor receptor 2 and fibroblast growth factor receptor 3 genes associated with human gastric and colorectal cancers. Cancer Res 2001; 61:3541-3543.
150. Squires M, Ward G, Saxty G et al. Potent, selective inhibitors of fibroblast growth factor receptor define fibroblast growth factor dependence in preclinical cancer models. Mol Cancer Ther 2011;10: 1542-1552.
151. Lang SA, Klein D, Moser C et al. Inhibition of heat shock protein 90 impairs epidermal growth factor-mediated signaling in gastric cancer cells and reduces tumor growth and vascularization in vivo. Mol Cancer Ther 2007;6:1123-1132.
152. Weichert W, Roske A, Gekeler V et al. Association of patterns of class I histone deacetylase expression with patient prognosis in gastric cancer: A retrospective analysis. Lancet Oncol 2008;9:139-148.
153. Fetterly GJ, Brady WE, LeVea CM et al. A phase I pharmacokinetic (PK) study of vorinostat (V) in combination with irinotecan (I), 5-fluorouracil (5FU), and leucovorin (FOLFIRI) in advanced upper gastrointestinal cancers (AGC). J Clin Oncol 2009; 27(15 suppl):el5540.
154. Chiba T, Marusawa H, Seno H et al. Mechanism for gastric cancer development by Helicobacter pylori infection. J Gastroenterol Hepatol 2008;23: 1175-1181.